TheraDiag SA (ALTER):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:TheraDiag SA (ALTER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11478
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Theradiag SA (Theradiag), formerly Biomedical Diagnostics SA, is a biotechnology company that develops, manufactures, and markets vitro diagnostic products. The company offers product for the diagnostics of auto-immune diseases, allergies and infectious diseases. It develops product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. Theradiag provides tests using techniques and automatic devices and solutions for high-speed diagnostics. The company also offers multi-parametric monitoring system for treatment of autoimmune diseases by anti-TNF. It provides in-vitro diagnostic products in the fields of auto-immunity, allergies, infectious diseases and, more recently, oncology and molecular biology. The company serves autoimmune disease diagnostic markets. Theradiag is headquartered in Paris, France.

TheraDiag SA (ALTER) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TheraDiag SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
TheraDiag SA, Medical Devices Deals, 2012 to YTD 2018 9
TheraDiag SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
TheraDiag SA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
TheraDiag Enters Into Co-Development Agreement With Regional Cancer Institute of Montpellier 11
Equity Offering 12
TheraDiag Raises USD4.5 Million in Private Placement of Shares 12
TheraDiag Raises USD2.78 Million in Private Placement of Shares 13
TheraDiag Raises Funds in IPO of Shares 14
Acquisition 15
Theradiag Acquires Prestizia, Developer Of microRNA Technology 15
TheraDiag SA – Key Competitors 16
TheraDiag SA – Key Employees 17
TheraDiag SA – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Strategy And Business Planning 19
Dec 19, 2017: THERADIAG provides an update on Prestizia and its partnership with HOB Biotech 19
Financial Announcements 20
Sep 19, 2018: Theradiag: 2018 interim results and business update 20
Apr 10, 2018: Theradiag reports its 2017 annual results and sales for first quarter 2018 22
Feb 20, 2018: Theradiag Announces 2017 Annual Sales and Cash Flow at End 2017 24
Oct 26, 2017: Theradiag: Revenues at the end of September 30, 2017 25
Sep 19, 2017: Theradiag: Results and activity for the first half of 2017 Continued improvement in results 26
Jul 25, 2017: Theradiag: Further Strong Sales Growth in the First Half of 2017: +9% 28
Apr 27, 2017: THERADIAG Announces First-quarter 2017 Revenues 29
Apr 27, 2017: Theradiag: First-Quarter 2017 Revenues 30
Mar 01, 2017: THERADIAG: Full-year 2016 results 31
Corporate Communications 33
Oct 09, 2018: Evolution of Theradiag’s governance 33
Mar 01, 2017: Appointment of Dominique Costantini and Dominique Takizawa to Theradiag’s Board of Directors 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
TheraDiag SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TheraDiag SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TheraDiag SA, Deals By Therapy Area, 2012 to YTD 2018 8
TheraDiag SA, Medical Devices Deals, 2012 to YTD 2018 9
TheraDiag SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
TheraDiag Enters Into Co-Development Agreement With Regional Cancer Institute of Montpellier 11
TheraDiag Raises USD4.5 Million in Private Placement of Shares 12
TheraDiag Raises USD2.78 Million in Private Placement of Shares 13
TheraDiag Raises Funds in IPO of Shares 14
Theradiag Acquires Prestizia, Developer Of microRNA Technology 15
TheraDiag SA, Key Competitors 16
TheraDiag SA, Key Employees 17
TheraDiag SA, Subsidiaries 18

List of Figures
TheraDiag SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TheraDiag SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TheraDiag SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
TheraDiag SA, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[TheraDiag SA (ALTER):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • British Columbia Cancer Agency:製薬・医療:M&Aディール及び事業提携情報
    Summary British Columbia Cancer Agency (BC Cancer Agency), a subsidiary of Provincial Health Services Authority is a healthcare service center that provides comprehensive cancer control program. The center offers services such as diagnostic and therapy planning, radiation therapy, patient assessment …
  • British Polythene Industries PLC:企業の戦略・SWOT・財務情報
    British Polythene Industries PLC - Strategy, SWOT and Corporate Finance Report Summary British Polythene Industries PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Posco International Corp (047050):企業の財務・戦略的SWOT分析
    Posco International Corp (047050) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Adani Enterprises Ltd (ADANIENT):企業の財務・戦略的SWOT分析
    Adani Enterprises Ltd (ADANIENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Ocular Therapeutix Inc (OCUL):企業の財務・戦略的SWOT分析
    Summary Ocular Therapeutix Inc (Ocular Therapeutix), formerly I-Therapeutix Inc, is a biopharmaceutical company that discovers, develops and commercializes therapies for treating eye diseases. The company’s lead product candidate DEXTENZA is used for the treatment of post-surgical ocular inflammatio …
  • Gfk SE (GFK):企業の財務・戦略的SWOT分析
    Summary GfK SE (GfK) is a business service provider that offers market and consumer services. The company provides solutions such as online pricing intelligence, brand and customer experience, point of sales analytics, digital marketing intelligence, consumer panels, product catalogs, market opportu …
  • Ignyta Inc (RXDX)-医療機器分野:企業M&A・提携分析
    Summary Ignyta Inc (Ignyta), formerly NexDx Inc is a drug manufacturing company that discovers, develops and commercializes new drugs targeting activated genes in cancer cells for the treatment of cancer patients. The company develops products using integrated therapeutic (Rx) and companion diagnost …
  • Abengoa SA (ABG):電力:M&Aディール及び事業提携情報
    Summary Abengoa SA (Abengoa) is an applied engineering and equipment manufacturer. It employs novel technological solutions for sustainability in infrastructures, energy and water sectors. The company provides integrated project solutions. Abengoa’s solutions include engineering, and operation and m …
  • Aeris Resources Limited:企業の戦略・SWOT・財務情報
    Aeris Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Aeris Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Avior Integrated Products Inc.:企業の戦略・SWOT・財務情報
    Avior Integrated Products Inc. - Strategy, SWOT and Corporate Finance Report Summary Avior Integrated Products Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Hertel Holding BV:企業の戦略的SWOT分析
    Hertel Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Emerald Health Therapeutics Inc (EMH):製薬・医療:M&Aディール及び事業提携情報
    Summary Emerald Health Therapeutics Inc (Emerald Health), formerly T-Bird Pharma Inc, is a producer of pharmaceutical grade medical cannabis. The company extracts and markets dried cannabis, and cannabis oils and capsules. It offers cannabinoid medicines, which are present in an unparalleled opportu …
  • Italiaonline SpA:企業の戦略的SWOT分析
    Italiaonline SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Erytech Pharma SA (ERYP):企業の財務・戦略的SWOT分析
    Summary Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that provides development of therapies for rare forms of cancer and orphan diseases. The company develops pipeline of product candidates through its proprietary ERYCAPS platform. It offers product candidates which are …
  • BBX Capital Corporation:企業のM&A・事業提携・投資動向
    BBX Capital Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BBX Capital Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Fenchem Inc:企業の戦略・SWOT・財務分析
    Fenchem Inc - Strategy, SWOT and Corporate Finance Report Summary Fenchem Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • AECOM (ACM):電力:M&Aディール及び事業提携情報
    Summary AECOM, formerly AECOM Technology Corporation, is a provider of engineering, consulting and project management services. The company primarily designs, builds, operates and finances various infrastructure assets for businesses, governments, and organizations. Its service offerings include ass …
  • General Biologicals Corp (4117)-医療機器分野:企業M&A・提携分析
    Summary General Biologicals Corp (GBC) is a medical device company that develops and manufactures diagnostics and pharmaceutical products. The company provides in-vitro diagnostic devices. It offers liver inspection tools such as test reagents and equipment. GBC’s products include real-time PCR kits …
  • Tragara Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tragara Pharmaceuticals Inc (Tragara Pharmaceuticals) is a pharmaceutical company focused on the clinical and commercial development of its proprietary medicines for the treatment of various cancers. Its lead product candidate TG02, an oral multi-kinase inhibitor facilitates anti-tumor activ …
  • Aevi Genomic Medicine Inc (GNMX):医療機器:M&Aディール及び事業提携情報
    Summary Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company provides pipeline products such as AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glut …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆